UB Paderborn / Katalog / Suche / in CDI

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Haematologica, 2008-03, Vol.93 (3), p.431-438

2008

Link zum Volltext

Verfügbarkeit prüfen

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing

Leukemia, 2018-03, Vol.32 (3), p.685-693

2018

Link zum Volltext

Verfügbarkeit prüfen

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

Leukemia, 2017-06, Vol.31 (6), p.1363-1367

2017

Link zum Volltext

Verfügbarkeit prüfen

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER‐DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)

HemaSphere, 2023-05, Vol.7 (S2), p.13-14

2023

Link zum Volltext

Verfügbarkeit prüfen

P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS

HemaSphere, 2022-06, Vol.6 (Suppl), p.766-767

2022

Link zum Volltext

Verfügbarkeit prüfen

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma

Leukemia, 2017-08, Vol.31 (8), p.1816-1819

2017

Link zum Volltext

Verfügbarkeit prüfen

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA ‐ SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION

HemaSphere, 2022-06, Vol.6 (Suppl), p.757-758

2022

Link zum Volltext

Verfügbarkeit prüfen

The chemokine CXCL9 (MIG) is an independent predictor of overall survival in newly diagnosed multiple myeloma

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e237-e238

2015

Link zum Volltext

Verfügbarkeit prüfen

Preclinical Analysis of Feasibility and Efficacy of CS1 Directed CAR T cell Therapy in Multiple Myeloma in the Autologous Setting

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e39-e39

2015

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Pre-approval Carfilzomib-Based Therapy of Multiple Myeloma in Daily Practice – Experience from a German Academic Center

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e284-e284

2015

Link zum Volltext

Verfügbarkeit prüfen

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma

Annals of oncology, 2007-07, Vol.18 (suppl-9), p.ix64-ix70

2007

Link zum Volltext

Verfügbarkeit prüfen

The Contribution of a Third Autologous Stem Cell Transplant in the Era of Novel Agents: Favourable Overall Survival and Improvement of Exhausted Bone Marrow Function

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e287-e288

2015

Link zum Volltext

Verfügbarkeit prüfen

An agent-based model approach to multi-phase life-cycle for contact inhibited, anchorage dependent cells

Interdisciplinary sciences : computational life sciences, 2014-12, Vol.6 (4), p.312-322

2014

Link zum Volltext

Verfügbarkeit prüfen

Expression of MUM1 IRF4 mRNA as a prognostic marker in patients with multiple myeloma

Leukemia, 2008-02, Vol.22 (2), p.441-445

2008

Link zum Volltext

Verfügbarkeit prüfen

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

Journal of cancer research and clinical oncology, 2019-03, Vol.145 (3), p.561-571

2019

Link zum Volltext

Verfügbarkeit prüfen

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Blood, 2016-12, Vol.128 (22), p.3335-3335

2016

Link zum Volltext

Verfügbarkeit prüfen

Studies on the Chemistry of Thienoannelated O,N- and S,N-Containing Heterocycles. Part 19[1]: Thieno[2,3-b][1,4]thiazines with Calcium Antagonistic and Potassium Opening Activities

Archiv der Pharmazie (Weinheim), 2000-03, Vol.333 (2-3), p.58-62

2000

Link zum Volltext

Verfügbarkeit prüfen

Comparison of Immune Cell Response to Cytomegalovirus Proteins Versus Peptides using an IFN-gamma Elispot Assay to Monitor cytomegalovirus-specific Immunity after Hematopoietic Stem Cell Transplantation

BONE MARROW TRANSPLANTATION, 2020, Vol.55 (SUPPL 1), p.457

2020

Link zum Volltext

Verfügbarkeit prüfen

Standardized Monitoring of cytomegalovirus-specific Cellular Immunity can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation

BONE MARROW TRANSPLANTATION, 2020, Vol.55 (SUPPL 1), p.470

2020

Link zum Volltext

Verfügbarkeit prüfen

PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA‐THAL‐DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

HemaSphere, 2019-06, Vol.3 (S1), p.695-696

2019

Link zum Volltext

Verfügbarkeit prüfen

Continuous treatment with lenalidomide in multiple myeloma: a case report

Memo - Magazine of European medical oncology, 2012-04, Vol.5 (1), p.23-26

2012

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing

IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)

P08 TEMPORAL TRENDS IN PROGNOSIS OF PATIENTS WITH SMOLDERING MULTIPLE MYELOMA (SMM) WHO MEET CRITERIA FOR BIOMARKER‐DEFINED EARLY MULTIPLE MYELOMA (SLIM CRAB POSITIVE MM)

P873: CARFILZOMIB RESISTANCE IS ASSOCIATED WITH SIGNIFICANT DEREGULATION OF THE BH3 FAMILY PROTEINS

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma

P864: CTPS1 IS A NOVEL THERAPEUTIC TARGET IN MYELOMA ‐ SELECTIVE SMALL MOLECULE INHIBITION DELIVERS SINGLE AGENT ACTIVITY AND SYNERGISES WITH ATR INHIBITION

The chemokine CXCL9 (MIG) is an independent predictor of overall survival in newly diagnosed multiple myeloma

S179: RANDOMIZED COMPARISON BETWEEN KRD AND KTD INDUCTION, FOLLOWED BY K MAINTENANCE OR OBSERVATION IN TRANSPLANT NON‐ELIGIBLE PATIENTS WITH NDMM (AGMT‐MM02 TRIAL)

Preclinical Analysis of Feasibility and Efficacy of CS1 Directed CAR T cell Therapy in Multiple Myeloma in the Autologous Setting

Efficacy and Safety of Pre-approval Carfilzomib-Based Therapy of Multiple Myeloma in Daily Practice – Experience from a German Academic Center

Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma

The Contribution of a Third Autologous Stem Cell Transplant in the Era of Novel Agents: Favourable Overall Survival and Improvement of Exhausted Bone Marrow Function

An agent-based model approach to multi-phase life-cycle for contact inhibited, anchorage dependent cells

Expression of MUM1 IRF4 mRNA as a prognostic marker in patients with multiple myeloma

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance

Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial

Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation

Studies on the Chemistry of Thienoannelated O,N- and S,N-Containing Heterocycles. Part 19[1]: Thieno[2,3-b][1,4]thiazines with Calcium Antagonistic and Potassium Opening Activities

Comparison of Immune Cell Response to Cytomegalovirus Proteins Versus Peptides using an IFN-gamma Elispot Assay to Monitor cytomegalovirus-specific Immunity after Hematopoietic Stem Cell Transplantation

Standardized Monitoring of cytomegalovirus-specific Cellular Immunity can Improve Risk Stratification of Recurrent Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation

PS1509 QUALITY OF LIFE IN PATIENTS WITH RRMM DURING IXA‐THAL‐DEX INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN COMPARISON TO THE GENERAL POPULATION

Continuous treatment with lenalidomide in multiple myeloma: a case report

Clinical Validation of a Novel Elispot-Based in Vitro Diagnostic Assay: Monitoring Cytomegalovirus-Specific Cell-Mediated Immunity and Risk Stratification in Hematopoietic Stem Cell Transplant Recipients

Suchergebnisse filtern